Document Detail

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
MedLine Citation:
PMID:  8590785     Owner:  NLM     Status:  MEDLINE    
Gastric inhibitory polypeptide (tGIP) and truncated glucagon like peptide-1 (GLP-1) are potent gastrointestinal insulinotropic factors (incretin), are most released after a meal or ingestion of glucose in man and animals. To investigate whether sulfonylurea (SU) affects the secretion of incretin, the modulation of plasma GIP and tGLP-1 levels following glucose ingestion in non-insulin-dependent diabetic type 2 patients with or without SU therapy was studied. A 75-G oral glucose tolerance test (OGTT) was carried out on 9 healthy subjects (controls) and 18 patients with non-obese type 2, 9 of whom were treated by diet alone (NIDDM-diet) and the other 9 with SU (glibenclamide 2.5 mg or gliclazide 40 mg) once a day (NIDDM-SU). Plasma GIP was measured by radioimmunoassay (RIA) with R65 antibody, and GLP-1 was measured by RIA with N-terminal-directed antiserum R1043 (GLP-1NT) and C-terminal-directed antiserum R2337 (GLP-1CT). Following OGTT, plasma glucose, GIP, GLP-1NT, and GLP-1CT in type 2 patients increased more markedly than in controls, despite the lower response of insulin. However, there were no significant differences in plasma levels of these peptides between the NIDDM-diet and NIDDM-SU groups. Therefore, it is unlikely that SU is involved in the high response of GIP and GLP-1s to OGTT in type 2 patients.
N Fukase; H Manaka; K Sugiyama; H Takahashi; M Igarashi; M Daimon; K Yamatani; M Tominaga; H Sasaki
Related Documents :
15183115 - Prior in vitro exposure to glp-1 with or without gip can influence the subsequent beta ...
16722815 - Exenatide: a glp-1 receptor agonist as novel therapy for type 2 diabetes mellitus.
8725855 - Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-li...
11832995 - Resistance of succinic acid dimethyl ester insulinotropic action to exendin (9-39) amide.
20530705 - Glucagon-like peptide-1 analog and insulin combination therapy in the management of adu...
15948715 - Endothelial function and baroreflex sensitivity according to the oral glucose tolerance...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta diabetologica     Volume:  32     ISSN:  0940-5429     ISO Abbreviation:  Acta Diabetol     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1996-04-01     Completed Date:  1996-04-01     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  9200299     Medline TA:  Acta Diabetol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  165-9     Citation Subset:  IM    
Third Department of Internal Medicine, Yamagata University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Blood Glucose / analysis
Diabetes Mellitus, Type 2 / blood*,  drug therapy
Gastric Inhibitory Polypeptide / blood*
Glucagon / blood*
Glucagon-Like Peptide 1
Glucose / administration & dosage,  pharmacology*
Insulin / blood
Peptide Fragments / blood*
Protein Precursors / blood*
Sulfonylurea Compounds / therapeutic use
Reg. No./Substance:
0/Blood Glucose; 0/Peptide Fragments; 0/Protein Precursors; 0/Sulfonylurea Compounds; 11061-68-0/Insulin; 50-99-7/Glucose; 59392-49-3/Gastric Inhibitory Polypeptide; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of short-term culturing on islet phosphoinositide and insulin secretory responses to glucose...
Next Document:  Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density l...